NeurAxon Focusing On Migraine With Aura For nNOS Inhibitor
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Based on a post-hoc analysis of a failed Phase II trial, NeurAxon will focus further development of the neuronal nitric oxide synthase inhibitor on the subset of migraine patients who experience aura
You may also be interested in...
GSK/Pozen Win Long-awaited Approval For Combo Migraine Drug
Treximet will hit the U.S. market in mid-May, GSK says.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.